Stock GWLL GOLDENWELL BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Goldenwell Biotech, Inc.

Equities

GWLL

US38138N1046

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 18:01:50 08/05/2024 BST 		5-day change 1st Jan Change
0.2 USD +241.30% Intraday chart for Goldenwell Biotech, Inc. +241.30% +241.30%
04-12 Goldenwell Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Goldenwell Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 29.2 5.801
Enterprise Value (EV) 1 29.18 5.748
P/E ratio -28.9 x -48.3 x
Yield - -
Capitalization / Revenue 611 x 2,479 x
EV / Revenue 611 x 2,456 x
EV / EBITDA - -
EV / FCF -41,504,838 x -80,029,084 x
FCF Yield -0% -0%
Price to Book 145 x 68.5 x
Nbr of stocks (in thousands) 99,000 99,000
Reference price 2 0.2950 0.0586
Announcement Date 13/04/23 12/04/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 0.00087 - 0.016 0.0478 0.00234
EBITDA - - - - -
EBIT 1 -0.006933 -0.006368 -0.1183 -0.9851 -0.1169
Operating Margin -796.9% - -740.7% -2,060.89% -4,995.51%
Earnings before Tax (EBT) 1 -0.006933 -0.006324 -0.117 -0.9851 -0.1169
Net income 1 -0.006933 -0.006324 -0.117 -0.9851 -0.1169
Net margin -796.9% - -732.64% -2,060.87% -4,995.51%
EPS - -0.000078 -0.001280 -0.0102 -0.001212
Free Cash Flow - - - -0.7032 -0.0718
FCF margin - - - -1,471.04% -3,069.49%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 21/02/20 23/07/21 01/04/22 13/04/23 12/04/24
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 0.25 0.25 0.17 0.02 0.05
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - -0.7 -0.07
ROE (net income / shareholders' equity) - -2.55% -42.5% -391% -81.6%
ROA (Net income/ Total Assets) - -1.61% -20.8% -174% -30.7%
Assets 1 - 0.3934 0.5615 0.5675 0.3812
Book Value Per Share 2 0 0 0 0 0
Cash Flow per Share 2 0 0 0 0 0
Capex - - - - -
Capex / Sales - - - - -
Announcement Date 21/02/20 23/07/21 01/04/22 13/04/23 12/04/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GOLDENWELL BIOTECH, INC. Stock Goldenwell Biotech, Inc.
+241.30% 19.8M
MODERNA, INC. Stock Moderna, Inc.
+23.37% 46.71B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.94% 41.52B
CELLTRION, INC. Stock Celltrion, Inc.
-5.86% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.29% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.92% 19.26B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+3.20% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.67% 12.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.23% 11.98B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GWLL Stock
  4. Financials Goldenwell Biotech, Inc.